Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etoricoxib + diacerein
- Development stage
- Phase 3
- Lead developer
- Liomont
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
etoricoxib + diacerein is a fixed-dose combination therapy developed by Laboratorios Liomont for the treatment of pain associated with osteoarthritis, specifically targeting knee and hip joints. Etoricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor that provides rapid analgesic and anti-inflammatory effects by reducing prostaglandin synthesis. Diacerein is an anthraquinone derivative that acts as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) by inhibiting interleukin-1 beta (IL-1β), a key pro-inflammatory cytokine involved in cartilage degradation and joint inflammation. This combination aims to provide both immediate symptomatic relief and potential long-term disease-modifying benefits in patients with osteoarthritis.
- Brand names
- Artrocox D
- Other names
- diacerein + etoricoxib
02
Targets
ALOX12 (Arachidonate 12-lipoxygenase, 12S type)NAT (Arylamine N-acetyltransferase 2)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)CYP3A (CYP3A family)NR1H3 (Liver X receptor beta)LXRB (Liver X receptor beta)IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on etoricoxib + diacerein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etoricoxib + diacerein.